Case Study 1: Two Announcements, One Indication

A worked application of §36.2's six questions.

Everything below is a [constructed teaching example]. Both announcements were written for this book. They describe no real compound, company, trial, or investigator. The point is not the compounds — it is that two pieces of text can generate near-identical press coverage while carrying entirely different evidentiary weight, and that six questions separate them in about two minutes.

Dated to the chapter's frame: as of this writing, in 2026.

The setup

Suppose that in the same month, two companies announce progress in the same indication: reducing cardiovascular events in adults with obesity and established cardiovascular disease.

Both announcements are picked up. Both produce headlines with the word "breakthrough." Both are forwarded by people who mean well. A reader who has not learned to separate them will come away believing the field advanced twice.

It advanced once.

Announcement A [constructed teaching example]

"COMPANY A REPORTS POSITIVE PHASE 3 RESULTS FOR ITS LEAD CANDIDATE IN CARDIOVASCULAR RISK REDUCTION

In a randomized, double-blind trial of 8,400 adults with obesity and established cardiovascular disease, the candidate reduced the primary composite endpoint — cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — compared with an active comparator already recommended in treatment guidelines, over a median follow-up of 3.9 years. The difference was statistically significant on the prespecified primary analysis. Discontinuation for adverse events was higher in the candidate arm. Full results were published simultaneously in a peer-reviewed journal and presented at a scientific meeting; the protocol and statistical analysis plan are available as supplementary material."

Announcement B [constructed teaching example]

"COMPANY B ANNOUNCES BREAKTHROUGH IN CARDIOVASCULAR PROTECTION WITH FIRST-IN-CLASS PEPTIDE

Company B today announced encouraging first-in-human data for its novel peptide, which targets a previously undrugged receptor implicated in vascular inflammation. In the Phase 1 study, the compound was generally well tolerated across all dose cohorts, and exploratory biomarker analyses showed favorable trends in markers of inflammation. 'This is a fundamentally new approach to cardiovascular disease,' said the company's chief scientific officer. 'The biology here is extraordinarily compelling, and we believe it has the potential to change how this disease is treated.' Data will be presented at an upcoming conference."

Running the six questions

Question 1 — What phase, actually?

A: Phase 3. Randomized, double-blind, 8,400 participants, nearly four years of follow-up. This is the stage at which regulators make decisions.

B: Phase 1. First-in-human. The study's design purpose is safety, tolerability, and pharmacokinetics. It is not built to detect efficacy and cannot be read as having failed to.

What separates them: these are not adjacent rungs. Chapter 10's attrition figure applies most brutally to compounds at B's stage. Most compounds entering human trials never reach approval, and the great majority of that attrition happens after phase 1. B's announcement is, against the base rate, a report that a compound has cleared the first of several filters that most compounds do not clear.

Note also that B's headline names the indication — cardiovascular protection — while the study measured tolerability and inflammatory markers in a small number of people.

Question 2 — What endpoint?

A: A hard composite outcome — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke. These are events people would care about with no measurement involved.

B: Exploratory biomarkers. Two words are doing heavy lifting: exploratory means the analyses were not the study's prespecified purpose, and trends means the language of statistical significance was unavailable. Neither word is dishonest. Both are precise, and both are usually dropped in press coverage.

What separates them: A measured what matters. B measured something believed to correlate with what matters, in analyses that were not the point of the study. Chapter 16's whole argument lives in this gap.

Question 3 — What population?

A: Adults with obesity and established cardiovascular disease — a population at high enough baseline risk that events accumulate fast enough to be counted, which is why the trial could be run at all. This is also, roughly, the population that would receive the drug, though real-world patients will be older and sicker than any trial cohort.

B: Not stated in the announcement. First-in-human studies are frequently conducted in healthy volunteers, who do not have the disease the compound is aimed at.

What separates them: A's population and its target population overlap. B's population may share no relevant characteristic with the eventual target population at all.

Question 4 — Against what comparator?

A: An active comparator already recommended in guidelines. This is the hardest available test. Beating a therapy that already works is a categorically stronger result than beating placebo, which is in turn stronger than beating nothing. This single feature is why A's result would change practice.

B: None stated. Phase 1 studies typically include a placebo arm for safety comparison, but no comparator is mentioned, and the biomarker "trends" have no stated reference.

Question 5 — Who is claiming, and when?

A: A press release, but one that points at a simultaneous peer-reviewed publication, a conference presentation, and public availability of the protocol and statistical analysis plan. The company is the announcer; the evidence is checkable by someone who is not the company.

B: A press release quoting two company executives. No publication. Data "will be presented" at a future meeting. Everything a reader can evaluate has been written by a party with an interest in how it is received.

What separates them: A's claim is verifiable against a source that had an adversarial reviewer. B's is not verifiable at all yet. Note the vocabulary difference too: A reports numbers and names its analysis; B reports adjectives — encouraging, favorable, extraordinarily compelling.

Question 6 — What is the base rate?

A: A compound with a completed, published phase 3 trial on a hard outcome against an active comparator has moved almost as far off the base rate as anything can. The remaining uncertainty is about generalization, long-term safety, and real-world adherence — not about whether it works in the studied population.

B: A compound that has completed phase 1 sits close to the base rate. The mechanism story — "a previously undrugged receptor implicated in vascular inflammation" — is exactly the sort of account that does not move the base rate at all (rating rule 3). Every compound that failed in phase 2 had one.

The comparison, on one page

                        ANNOUNCEMENT A            ANNOUNCEMENT B
  1. Phase              Phase 3, completed        Phase 1, completed
  2. Endpoint           hard composite outcome    exploratory biomarkers, "trends"
  3. Population         target population,        not stated; possibly healthy
                        high baseline risk        volunteers
  4. Comparator         ACTIVE comparator         none stated
                        already in guidelines
  5. Source             press release POINTING    press release quoting executives;
                        AT peer-reviewed paper    no publication; data "will be
                        + protocol + SAP          presented"
  6. Base rate          moved far off it          sitting on it; mechanism story
                                                  does not move it

  HONEST ONE-LINE SUMMARY OF WHAT EACH SUPPORTS:
    A — this drug reduced major cardiovascular events versus an already-effective
        therapy in a defined population over about four years.
    B — this compound has been given to humans and nothing stopped the program.

Both of those are real information. They are not the same amount of it.

What a reader is meant to notice

Announcement A discloses something inconvenient. "Discontinuation for adverse events was higher in the candidate arm" is not there by accident, and its presence is itself a signal about the announcement's character. Releases that report a downside alongside the headline are behaving differently from releases that do not.

Announcement B contains no false statement. This is the important part. Every clause is defensible. "Generally well tolerated" is standard, accurate phase 1 language. "Exploratory" and "trends" are the correct technical words. The chief scientific officer's quotation is an opinion, clearly labeled as one. The announcement misleads entirely through selection, emphasis, and the reader's own willingness to fill gaps.

The mechanism is doing all the persuasive work in B. "A previously undrugged receptor implicated in vascular inflammation" is genuinely interesting and tells you nothing about whether the compound helps anyone. Chapter 5's discipline — knowing how something would work is not evidence that it does — is the entire defense here.

Coverage will flatten them. Both will be described as "in clinical trials." Both will attract the word "promising." A clinic marketing email might reference B's mechanism as though it were established biology. Only the six questions keep them apart.

Discussion Questions

1. Announcement B is accurate in every clause and misleading overall. Is it wrong to publish it? Distinguish the position of the company, the journalist who covers it, and the reader who forwards it.

2. Which of the six questions did the most work in separating A from B? Which did the least? Would your answer change if B had been a phase 2 announcement instead?

3. Announcement A discloses higher discontinuation for adverse events. Construct the strongest argument that this disclosure should increase your confidence in the rest of the release, and then the strongest argument that it should not.

4. Suppose B's compound is genuinely excellent and eventually works. Was the skeptical reading wrong? Answer using the distinction between a good decision and a good outcome, and connect it to rating rule 2 — that ❌ describes evidence, not potential.

5. Rewrite Announcement B so that it is equally accurate but not misleading — same facts, no overclaiming. What did you have to remove, and what did you have to add? Would a communications department plausibly approve your version?

6. A friend sends you both headlines and says "two big advances this month." You have ninety seconds. What do you say, and what do you deliberately leave out in order to be understood?